Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.72 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKACG | P22612 | 1/20 | 0.55 |
| ▸ | PRKACB | P22694 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211530 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL20589783 | 0.86 | PDE4A (0.57) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL2801448 | 0.85 | HRH4 (0.53) | PIK3CAPIK3R1KDM4EMTORSMN1; SMN2 | |
| SCHEMBL17555334 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL13298350 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL27953666 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL12110480 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3R1KDM4EMTORPIK3CD | |
| SCHEMBL31259506 | 0.82 | HTR2C (0.61) | PIK3CAPIK3R1KDM4EMTORHTR1A | |
| SCHEMBL31259505 | 0.82 | HTR2C (0.61) | PIK3CAPIK3R1KDM4EMTORHTR1A | |
| SCHEMBL4439784 | 0.80 | PIK3CA (0.48) | PIK3CAPIK3R1KDM4EMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | claimed |
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | claimed |
| US-8354528-B2 | Process for making thienopyrimidine compounds | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3849554-B1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-119161359-A | Novel 4-morpholinyl thieno [3,2-d ] pyrimidine compound containing acrylamide structure and application thereof | 辽宁大学 | 2024-12-20 | — | — | CN | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-4256738-A | BACTERICIDES, PYRIMIDINYL, QUINAZOLINYL | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0001981-A1 | 9-(Omega-heteroarylamino-alkylamino)-erythromycins, their salts, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | PIK3CA 218/4885PIK3R1 341/4885KDM4E 2695/4885 |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 16/4885KDM4E 1752/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885KDM4E 868/4885 |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | PDPK1, PDCD1, PDCD1LG2 | PIK3CA 30/4885PIK3R1 52/4885KDM4E 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.